Veru Inc. (VERU)
NASDAQ · Manufacturing · Pharmaceutical preparations
VERU price, last 12 months
Key stats
- Previous close
- $2.51
- Open
- $2.59
- Day range
- $2.50 – $2.59
- 52-week range
- $2.05 – $7.33
- Volume
- 106.6K
- Avg volume (20 days)
- 211.9K
- Market cap
- $43.3M
Performance
Technicals and fundamentals
About Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $43.3M